EXEL Exelixis, Inc. - Common Stock
$54,24
السعر · أغسطس 19, 2026
البيانات الأساسية اعتبارًا من أغسطس 5, 2026
نطاق 52 أسبوعًا
$34–$58
86% of range
تقييم المحللين
HOLD
26 analysts
السعر المستهدف
$53
P/E (TTM)
18.9
ROE
37.3%
هامش صافي الربح
33.7%
حول Exelixis, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
اقرأ المزيد
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
History
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.
By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.
In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million.
By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.
In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.
In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.
In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials.
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014.
Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees.
In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.
Finance
Pricing
Cabometyx (cabozantinib)
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
EXEL لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$54.24
القيمة السوقية
$13.76B
P/E (TTM)
18.9
ربح السهم (آخر 12 شهرًا)
$2.78
الإيرادات (آخر 12 شهرًا)
$2.32B
عائد التوزيعات
—
ROE
37.3%
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$34 – $58
EXEL مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$2.32B
2016-12-31
→
2026-01-02
ربح السهم
$2.78
2017-12-29
→
2026-01-02
التدفق النقدي الحر
$876M
2017-12-29
→
2026-01-02
الهوامش
33.7%
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
EXEL
متوسط الأقران
P/E (TTM)
18.9
28.5
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
5.9
20.1
P/B (السعر / القيمة الدفترية)
6.4
12.9
Price / FCF (السعر / التدفق النقدي الحر)
15.7
—
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
EXEL
متوسط الأقران
Operating Margin (هامش التشغيل)
37.6%
—
Net Profit Margin (هامش صافي الربح)
33.7%
-48.4%
ROA (العائد على الأصول)
27.0%
-28.4%
ROE
37.3%
-49.2%
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
EXEL
متوسط الأقران
Current Ratio (النسبة الحالية)
3.6
5.0
Quick Ratio (النسبة السريعة)
3.3
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
EXEL
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
7.0%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
12.9%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
18.6%
—
EPS YoY (ربحية السهم على أساس سنوي)
58.0%
—
Net Income YoY (صافي الدخل مقارنة بالعام السابق)
50.1%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
EXEL
متوسط الأقران
EXEL توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
26 محللين
- شراء قوي 5 19,2%
- شراء 8 30,8%
- احتفاظ 12 46,2%
- بيع 1 3,8%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
16 محللين · 2026-08-13
الوسيط
$52.00
الآن
$54.24
منخفض
$41.00
مرتفع
$66.00
السعر المستهدف الوسيط
$52.00
-4,1%
السعر المستهدف المتوسط
$52.94
-2,4%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
0.08%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $0.82 | $0.80 | 0.02% |
| 31 مارس، 2026 | $0.79 | $0.72 | 0.07% |
| 31 ديسمبر، 2025 | $0.88 | $0.82 | 0.06% |
| 30 سبتمبر، 2025 | $0.69 | $0.63 | 0.06% |
| 30 يونيو، 2025 | $0.65 | $0.57 | 0.08% |
| 31 مارس، 2025 | $0.55 | $0.37 | 0.18% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | $191M | $37M | |
| Cost of Revenue | $84M | $76M | $73M | $58M | $53M | $36M | $33M | $26M | $15M | $7M | $4M | |
| R&D Expense | $825M | $910M | $1.04B | $892M | $694M | $548M | $337M | $182M | $112M | $96M | $96M | |
| SG&A Expense | $519M | $492M | $543M | $460M | $402M | $293M | $228M | $206M | $159M | $116M | $57M | |
| Operating Expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877M | $598M | $415M | $287M | $220M | $159M | |
| Operating Income | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | $-28M | $-121M | |
| Interest Expense | · | · | · | · | · | · | $0 | $0 | $9M | $33M | $41M | |
| Other Non-op | $-198.0K | $-133.0K | $93.0K | $-197.0K | $-184.0K | $912.0K | $680.0K | $397.0K | $-4M | $5M | $-381.0K | |
| Pretax Income | · | · | · | · | · | $131M | $398M | $452M | $159M | $-70M | $-162M | |
| Income Tax | $159M | $160M | $50M | $52M | $63M | $19M | $77M | $-238M | $4M | $0 | $55.0K | |
| Net Income | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | $-70M | $-162M | |
| EPS (Basic) | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | · | $-0.77 | |
| EPS (Diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | · | $-0.77 | |
| Shares (Basic) | 271,567,000 | 290,030,000 | 318,151,000 | 321,526,000 | 314,884,000 | 308,271,000 | 302,584,000 | 297,892,000 | 293,588,000 | · | 209,227,000 | |
| Shares (Diluted) | 281,863,000 | 296,132,000 | 321,464,000 | 324,556,000 | 322,359,000 | 318,001,000 | 315,009,000 | 312,803,000 | 312,003,000 | · | 209,227,000 | |
| EBITDA | $901M | $633M | $197M | $222M | $300M | $119M | $378M | $444M | $167M | · | · |
الميزانية العمومية 27
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $482M | $217M | $263M | $501M | $647M | $319M | $267M | $315M | $183M | $152M | $142M | |
| Short-term Investments | $577M | $894M | $732M | $807M | $820M | $887M | $586M | $379M | $205M | $268M | · | |
| Receivables | $287M | $265M | $237M | $215M | $283M | $161M | $119M | $163M | $77M | $40M | · | |
| Inventory | $22M | $22M | $17M | $33M | $27M | $21M | $13M | $10M | $7M | $3M | · | |
| Prepaid Expense | $76M | $68M | $68M | $62M | $58M | $57M | $27M | $31M | $9M | $5M | · | |
| Current Assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897M | $485M | $469M | · | |
| PP&E (Net) | $99M | $119M | $129M | $111M | $104M | $67M | $49M | $51M | $26M | $2M | · | |
| PP&E (Gross) | $231M | $220M | $209M | $171M | $145M | $102M | $74M | $68M | $49M | $27M | · | |
| Accum. Depreciation | $132M | $101M | $80M | $61M | $41M | $35M | $26M | $17M | $23M | $25M | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | |
| Other Non-current Assets | · | · | · | · | $131M | $73M | $53M | $8M | $12M | $1M | · | |
| Total Assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Accounts Payable | $30M | $38M | $34M | $33M | $24M | $24M | $12M | $11M | $10M | $7M | · | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $80M | · | |
| Current Liabilities | $406M | $404M | $394M | $324M | $338M | $205M | $143M | $105M | $115M | $269M | · | |
| Capital Leases | $173M | $191M | $190M | $190M | $51M | $49M | $48M | $12M | $15M | · | · | |
| Other Non-current Liabilities | $104M | $109M | $94M | $69M | $8M | $721.0K | $2M | $1M | $2M | $541.0K | · | |
| Total Liabilities | $683M | $703M | $678M | $583M | $406M | $258M | $200M | $135M | $370M | $506M | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $189M | · | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | · | · | |
| Common Stock | $262.0K | $282.0K | $303.0K | $324.0K | $319.0K | $312.0K | $305.0K | $300.0K | $296.0K | $290.0K | · | |
| Paid-in Capital | $2.23B | $2.34B | $2.44B | $2.54B | $2.43B | $2.32B | $2.24B | $2.17B | $2.11B | $2.07B | · | |
| Retained Earnings | $-77M | $-99M | $-173M | $-34M | $-217M | $-448M | $-559M | $-880M | $-1.83B | $-1.98B | · | |
| AOCI | $3M | $-1M | $-4M | $-15M | $-758.0K | $4M | $3M | $-701.0K | $-347.0K | $-416.0K | · | |
| Stockholders' Equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $285M | $89M | $-141M | |
| Liabilities + Equity | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Shares Outstanding | 262,483,000 | 281,732,000 | 302,793,000 | 323,951,000 | 318,842,000 | 311,627,000 | 304,831,000 | 299,876,000 | 296,209,000 | 289,923,798 | 227,960,943 |
التدفق النقدي 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $29M | $29M | $26M | $21M | $14M | $9M | $8M | $5M | $1M | $1M | $1M | |
| Stock-based Comp | $113M | $94M | $106M | $108M | $120M | $105M | $57M | $41M | $24M | $23M | $22M | |
| Deferred Tax | $126M | $-59M | $-133M | $-60M | $47M | $15M | $71M | $-244M | $0 | $0 | $0 | |
| Restructuring | $21M | $34M | $0 | $0 | · | · | · | $0 | $-32.0K | $63M | $1M | |
| Other Non-cash | $-167M | $116M | $127M | $112M | $-10M | $-32M | $70M | $-76M | $-14M | · | · | |
| Operating Cash Flow | $884M | $700M | $333M | $363M | $401M | $209M | $527M | $416M | $166M | $206M | $-141M | |
| CapEx | $8M | $28M | $40M | $28M | $54M | $30M | $13M | $33M | $21M | $2M | $447.0K | |
| Investing Cash Flow | $350M | $-117M | $-27M | $-524M | $-43M | $-131M | $-587M | $-298M | $37M | $-216M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $0 | $0 | $-186M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $0 | $146M | |
| Stock Repurchased | $948M | $652M | $550M | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | $-948M | $-652M | $-550M | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-970M | $-629M | $-546M | $586.0K | $-15M | $-25M | $13M | $10M | $-170M | $20M | $152M | |
| Net Change in Cash | $265M | $-46M | $-240M | $-161M | $343M | $53M | $-48M | $128M | $32M | $10M | $61M | |
| Taxes Paid | $155M | $170M | $186M | $128M | $13M | $4M | $8M | $11M | $538.0K | · | · | |
| Free Cash Flow | $876M | $672M | $293M | $335M | $337M | $179M | $514M | $382M | $144M | · | · | |
| Levered FCF | · | · | · | · | · | · | $514M | $382M | $136M | · | · |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | · | · | |
| Net Margin | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | · | · | |
| Pretax Margin | · | · | · | · | · | 13.2% | 41.1% | 52.9% | 35.0% | · | · | |
| EBITDA Margin | 38.8% | 29.2% | 10.7% | 13.8% | 20.9% | 12.1% | 39.0% | 52.0% | 36.9% | · | · | |
| ROA | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.7% | · | · | |
| ROE | 37.3% | 23.1% | 9.0% | 7.3% | 10.7% | 6.0% | 19.5% | 62.6% | 82.4% | · | · | |
| ROIC | · | · | · | · | · | 5.0% | 17.7% | 52.0% | 56.6% | · | · |
السيولة والملاءة 4
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 | 7.1 | 7.1 | 8.5 | 4.2 | · | · | |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 | 6.7 | 6.8 | 8.1 | 4.1 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 19.1 | · | · |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.7 | · | · | |
| Inventory Turnover | 3.8 | 3.8 | 2.9 | 1.9 | 2.2 | 2.1 | 2.9 | 3.2 | 3.0 | · | · | |
| Receivables Turnover | 8.4 | 8.6 | 8.1 | 6.5 | 6.5 | 7.1 | 6.9 | 9.8 | 7.4 | · | · |
معدلات النمو 9
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 14.8% | 22.8% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 18.6% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 70.6% | 34.7% | 22.9% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 51.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 50.1% | 150.9% | 14.0% | -21.1% | 106.7% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 62.5% | 31.1% | 22.9% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 47.6% | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | · | $37M | |
| Net Income TTM | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | · | $-162M | |
| Market Cap | $11.44B | $9.57B | $7.26B | $5.20B | $5.83B | $6.25B | $5.19B | $5.83B | $9.00B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $8.62B | · | · | |
| P/E | 15.7 | 19.3 | 36.9 | 28.6 | 25.4 | 57.3 | 16.7 | 8.8 | 62.0 | · | -7.3 | |
| P/S | 4.9 | 4.4 | 4.0 | 3.2 | 4.1 | 6.3 | 5.4 | 6.8 | 19.9 | · | · | |
| P/B | 5.3 | 4.3 | 3.2 | 2.1 | 2.6 | 3.3 | 3.1 | 4.5 | 31.6 | · | · | |
| P / Tangible Book | 5.5 | 4.4 | 3.3 | 2.1 | 2.7 | 3.4 | · | · | · | · | · | |
| P / Cash Flow | 12.9 | 13.7 | 21.8 | 14.3 | 14.5 | 29.9 | 9.8 | 14.0 | 54.4 | · | · | |
| P / FCF | 13.1 | 14.3 | 24.8 | 15.5 | 17.3 | 35.0 | 10.1 | 15.2 | 62.3 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 51.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 59.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 19.0 | · | · | |
| Earnings Yield | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 6.0% | 11.4% | 1.6% | · | -13.7% |
قائمة الدخل 14
| المقياس | اتجاه | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $718M | $598M | $568M | $555M | $818M | $540M | $637M | $425M | $480M | $472M | $470M | $409M | $424M | $412M | |
| Cost of Revenue | $21M | $20M | $27M | $19M | $19M | $19M | $25M | $17M | $18M | $21M | $22M | $19M | $18M | $14M | $16M | $15M | |
| R&D Expense | $212M | $200M | $164M | $199M | $200M | $212M | $111M | $223M | $211M | $228M | $245M | $333M | $233M | $234M | $337M | $199M | |
| SG&A Expense | $148M | $140M | $161M | $124M | $135M | $137M | $81M | $112M | $132M | $114M | $131M | $138M | $142M | $131M | $119M | $115M | |
| Operating Expenses | $380M | $359M | $287M | $361M | $355M | $369M | $303M | $403M | $361M | $396M | $398M | $490M | $392M | $380M | $472M | $329M | |
| Operating Income | $248M | $251M | $431M | $237M | $214M | $187M | $516M | $136M | $276M | $29M | $82M | $-18M | $78M | $29M | $-48M | $83M | |
| Other Non-op | $54.0K | $219.0K | $207.0K | $-49.0K | $50.0K | $-245.0K | $-363.0K | $-29.0K | $-287.0K | $-89.0K | $-137.0K | $289.0K | $-5.0K | $-54.0K | $-337.0K | $-69.0K | |
| Income Tax | $51M | $57M | $43M | $59M | $46M | $46M | $128M | $37M | $67M | $12M | $18M | $5M | $19M | $8M | $-1M | $19M | |
| Net Income | $212M | $210M | $401M | $194M | $185M | $160M | $399M | $118M | $226M | $37M | $86M | $1M | $81M | $40M | $-30M | $73M | |
| EPS (Basic) | $0.85 | $0.81 | $1.57 | $0.72 | $0.68 | $0.57 | $1.43 | $0.41 | $0.78 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| EPS (Diluted) | $0.82 | $0.79 | $1.49 | $0.69 | $0.65 | $0.55 | $1.39 | $0.40 | $0.77 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| Shares (Basic) | 250,808,000 | 258,329,000 | -604,028,000 | 268,421,000 | 272,583,000 | 278,804,000 | -674,091,000 | 285,622,000 | 289,216,000 | 300,757,000 | -645,970,000 | 315,496,000 | 324,205,000 | 324,420,000 | 577,000 | 322,148,000 | |
| Shares (Diluted) | 259,675,000 | 267,322,000 | -609,119,000 | 278,535,000 | 284,393,000 | 288,177,000 | -676,699,000 | 291,478,000 | 293,974,000 | 305,530,000 | -651,367,000 | 319,247,000 | 327,305,000 | 326,279,000 | 136,000 | 325,066,000 | |
| EBITDA | $248M | $258M | · | $237M | $214M | $194M | · | $136M | $276M | $36M | · | $-18M | $78M | $36M | · | $83M |
الميزانية العمومية 24
| المقياس | اتجاه | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $281M | $226M | $482M | $376M | $164M | $184M | $217M | $258M | $198M | $260M | · | $397M | $464M | $541M | · | $675M | |
| Short-term Investments | $558M | $551M | $577M | $612M | $627M | $848M | $894M | $931M | $804M | $704M | · | $707M | $802M | $773M | · | $872M | |
| Receivables | $322M | $329M | $287M | $310M | $292M | $282M | $265M | $270M | $397M | $241M | · | $248M | $233M | $234M | · | $215M | |
| Inventory | $29M | $27M | $22M | $27M | $23M | $25M | $22M | $21M | $21M | $21M | · | $25M | $29M | $30M | · | $27M | |
| Prepaid Expense | $60M | $76M | $76M | $77M | $74M | $59M | $68M | $70M | $58M | $67M | · | $67M | $62M | $61M | · | $53M | |
| Current Assets | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B | $1.55B | $1.48B | $1.29B | · | $1.44B | $1.59B | $1.64B | · | $1.84B | |
| PP&E (Net) | $93M | $96M | $99M | $105M | $110M | $115M | $119M | $124M | $130M | $127M | · | $121M | $115M | $116M | · | $108M | |
| PP&E (Gross) | · | · | $231M | · | · | · | $220M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $132M | · | · | · | $101M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | $64M | $64M | $64M | · | $64M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $280M | |
| Total Assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Accounts Payable | $39M | $24M | $30M | $25M | $26M | $43M | $38M | $59M | $29M | $26M | · | $26M | $26M | $33M | · | $31M | |
| Current Liabilities | $362M | $371M | $406M | $374M | $336M | $399M | $404M | $394M | $346M | $373M | · | $377M | $340M | $328M | · | $302M | |
| Capital Leases | $166M | $170M | $173M | $176M | $180M | $187M | $191M | $194M | $198M | $201M | · | $191M | $195M | $187M | · | $160M | |
| Other Non-current Liabilities | $123M | $117M | $104M | $113M | $129M | $120M | $109M | $96M | $110M | $101M | · | $62M | $73M | $67M | · | $2M | |
| Total Liabilities | $650M | $658M | $683M | $663M | $645M | $706M | $703M | $685M | $653M | $676M | · | $629M | $615M | $588M | · | $470M | |
| Common Stock | $249.0K | $254.0K | $262.0K | $268.0K | $270.0K | $275.0K | $282.0K | $286.0K | $285.0K | $295.0K | · | $311.0K | $320.0K | $325.0K | · | $323.0K | |
| Paid-in Capital | $2.11B | $2.15B | $2.23B | $2.26B | $2.25B | $2.29B | $2.34B | $2.36B | $2.32B | $2.39B | · | $2.49B | $2.53B | $2.56B | · | $2.51B | |
| Retained Earnings | $-263M | $-216M | $-77M | $-106M | $-220M | $-163M | $-99M | $-90M | $-200M | $-259M | · | $-126M | $11M | $6M | · | $-4M | |
| AOCI | $-2M | $-415.0K | $3M | $4M | $1M | $2M | $-1M | $4M | $-5M | $-5M | · | $-14M | $-14M | $-9M | · | $-18M | |
| Stockholders' Equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B | $2.56B | $2.49B | $2.49B | |
| Liabilities + Equity | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Shares Outstanding | 248,885,000 | 253,701,000 | 262,483,000 | 268,098,000 | 270,132,000 | 275,033,000 | 281,732,000 | 285,780,000 | 285,222,000 | 295,032,000 | 302,793,000 | 310,970,000 | 320,253,000 | 324,985,000 | 323,951,000 | 322,541,000 |
التدفق النقدي 12
| المقياس | اتجاه | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $8M | $7M | $7M | $7M | $10M | $7M | $7M | $6M | $7M | $6M | $6M | $7M | $6M | $6M | |
| Stock-based Comp | $33M | $29M | $45M | $31M | $36M | $26M | $12M | $23M | $25M | $19M | $24M | $40M | $25M | $17M | $26M | $37M | |
| Restructuring | · | · | $-13M | $20M | $0 | $0 | $34M | $96.0K | $475.0K | $33M | · | $0 | $0 | $0 | · | · | |
| Other Non-cash | · | $5M | · | · | · | $19M | · | · | · | $6M | · | · | · | $21M | · | · | |
| Operating Cash Flow | $308M | $252M | $425M | $290M | $49M | $211M | $377M | $271M | $120M | $69M | $11M | $117M | $121M | $84M | $74M | $110M | |
| CapEx | $7M | $2M | $-16M | $1M | $3M | $3M | $1M | $8M | $7M | $10M | $13M | $9M | $6M | $12M | $10M | $43.0K | |
| Investing Cash Flow | $91M | $-51M | $374M | $25M | $248M | $50M | $-28M | $-217M | $82M | $112M | $62M | $35M | $-74M | $-50M | $-246M | $-69M | |
| Stock Repurchased | $323M | $430M | $486M | $104M | $302M | $284M | $311M | $12M | $264M | $185M | $209M | $217M | $124M | $0 | $0 | $0 | |
| Net Stock Activity | · | $-430M | · | · | · | $-284M | · | · | · | $-185M | · | · | · | · | · | · | |
| Financing Cash Flow | $-344M | $-457M | $-529M | $-104M | $-316M | $-295M | $-289M | $6M | $-262M | $-184M | $-206M | $-220M | $-125M | $5M | $-2M | $-2M | |
| Net Change in Cash | $55M | $-256M | $270M | $212M | $-19M | $-34M | $60M | $60M | $-61M | $-3M | $-134M | $-68M | $-78M | $39M | $-174M | $39M | |
| Free Cash Flow | · | $250M | · | · | · | $208M | · | · | · | $59M | · | · | · | $72M | · | · |
الربحية 5
| المقياس | اتجاه | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.5% | 41.1% | · | 39.6% | 37.6% | 33.6% | · | 25.2% | 43.3% | 6.9% | · | -3.7% | 16.6% | 7.0% | · | 20.1% | |
| Net Margin | 33.7% | 34.5% | · | 32.4% | 32.5% | 28.7% | · | 21.9% | 35.5% | 8.8% | · | 0.22% | 17.3% | 9.8% | · | 17.8% | |
| EBITDA Margin | 39.5% | 42.3% | · | 39.6% | 37.6% | 35.0% | · | 25.2% | 43.3% | 8.4% | · | -3.7% | 16.6% | 8.7% | · | 20.1% | |
| ROA | 8.2% | 7.8% | · | 6.7% | 6.8% | 5.7% | · | 4.0% | 7.6% | 1.2% | · | 0.04% | 2.7% | 1.4% | · | 2.7% | |
| ROE | 10.9% | 10.3% | · | 8.7% | 8.9% | 7.5% | · | 5.1% | 9.7% | 1.6% | · | 0.04% | 3.3% | 1.7% | · | 3.2% |
السيولة والملاءة 2
| المقياس | اتجاه | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.3 | · | 3.8 | 3.5 | 3.5 | · | 3.9 | 4.3 | 3.5 | · | 3.8 | 4.7 | 5.0 | · | 6.1 | |
| Quick Ratio | 3.2 | 3.0 | · | 3.5 | 3.2 | 3.3 | · | 3.7 | 4.0 | 3.2 | · | 3.6 | 4.4 | 4.7 | · | 5.8 |
الكفاءة 3
| المقياس | اتجاه | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.7 | 0.8 | · | 0.7 | 0.6 | 0.5 | · | 0.6 | |
| Receivables Turnover | 2.0 | 2.0 | · | 2.1 | 1.6 | 2.1 | · | 2.1 | 2.0 | 1.8 | · | 2.0 | 2.0 | 1.9 | · | 2.1 |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.41B | $2.33B | · | $2.26B | $2.30B | $2.16B | · | $2.07B | $2.00B | $1.78B | · | $1.76B | $1.71B | $1.60B | · | $1.52B | |
| Net Income TTM | $801M | $749M | · | $656M | $689M | $541M | · | $382M | $346M | $160M | · | $195M | $265M | $252M | · | $251M | |
| Market Cap | $13.90B | $11.13B | · | $10.75B | $12.47B | $9.51B | · | $7.42B | $6.41B | $7.00B | · | $6.79B | $6.12B | $6.31B | · | $5.06B | |
| P/E | 18.9 | 16.4 | · | 17.5 | 19.5 | 18.8 | · | 20.1 | 19.7 | 48.4 | · | 36.4 | 23.3 | 24.9 | · | 20.1 | |
| P/S | 5.8 | 4.8 | · | 4.8 | 5.4 | 4.4 | · | 3.6 | 3.2 | 3.9 | · | 3.9 | 3.6 | 4.0 | · | 3.3 | |
| P/B | 7.5 | 5.8 | · | 5.0 | 6.1 | 4.5 | · | 3.3 | 3.0 | 3.3 | · | 2.9 | 2.4 | 2.5 | · | 2.0 | |
| P / Tangible Book | 7.8 | 5.9 | · | 5.1 | 6.3 | 4.6 | · | 3.4 | 3.1 | 3.4 | · | 3.0 | 2.5 | 2.5 | · | 2.1 | |
| P / Cash Flow | · | 44.2 | · | · | · | 45.0 | · | · | · | 101.7 | · | · | · | 74.7 | · | · | |
| P / FCF | · | 44.5 | · | · | · | 45.6 | · | · | · | 118.4 | · | · | · | 87.1 | · | · | |
| Earnings Yield | 5.3% | 6.1% | · | 5.7% | 5.1% | 5.3% | · | 5.0% | 5.1% | 2.1% | · | 2.8% | 4.3% | 4.0% | · | 5.0% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| هامش الربح التشغيلي % | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| صافي الدخل | $783M | $521M | $208M | $182M | $231M |
| EPS المخفف | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
الميزانية العمومية
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 |
| النسبة السريعة | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 |
التدفق النقدي
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $876M | $672M | $293M | $335M | $337M |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
إشارات التداول إشارات شراء/بيع حديثة مع سعر الدخول ونسبة المخاطرة/المكافأة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 812 مقدمي إقرار · $9.1B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 136 (+23 مقابل الربع السابق) | 61 (-12 مقابل الربع السابق) | 242 (+1 مقابل الربع السابق) | 274 (+14 مقابل الربع السابق) | +14.7M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732794424 | 13468010 | 8,02% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $730617099 | 13427993 | 7,99% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655266268 | 12043122 | 7,17% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $595843747 | 10950997 | 6,52% | الأسهم |
| STATE STREET CORP | $542471563 | 9970071 | 5,93% | الأسهم |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485848030 | 8929389 | 5,31% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $362702104 | 6664894 | 3,97% | الأسهم |
| D. E. Shaw & Co., Inc. | $281389313 | 5171647 | 3,08% | الأسهم |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $237550034 | 4365926 | 2,60% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $229058537 | 4209861 | 2,51% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $221832835 | 4077060 | 2,43% | الأسهم |
| ASSETMARK, INC | $186834364 | 3433824 | 2,04% | الأسهم |
| Stephens Investment Management Group LLC | $147451698 | 2710011 | 1,61% | الأسهم |
| NORGES BANK | $146301199 | 2688866 | 1,60% | الأسهم |
| FIRST TRUST ADVISORS LP | $138383701 | 2543353 | 1,51% | الأسهم |
| Caisse de depot et placement du Quebec | $113950809 | 2094299 | 1,25% | الأسهم |
| GOLDMAN SACHS GROUP INC | $106578308 | 1958800 | 1,17% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $97484439 | 1791664 | 1,07% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $86563209 | 1590943 | 0,95% | الأسهم |
| Caligan Partners LP | $84512985 | 1553262 | 0,92% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $66309793 | 1218706 | 0,73% | الأسهم |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $63086055 | 1159457 | 0,69% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $58788318 | 1080469 | 0,64% | الأسهم |
| Robeco Institutional Asset Management B.V. | $56032453 | 1029819 | 0,61% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $51671488 | 949669 | 0,57% | الأسهم |
| FMR LLC | $48839667 | 897623 | 0,53% | الأسهم |
| Gotham Asset Management, LLC | $48569794 | 892663 | 0,53% | الأسهم |
| Swedbank AB | $45801141 | 841778 | 0,50% | الأسهم |
| Allspring Global Investments Holdings, LLC | $44544520 | 825510 | 0,49% | الأسهم |
| Retirement Systems of Alabama | $44107739 | 810655 | 0,48% | الأسهم |
| BOOTHBAY FUND MANAGEMENT, LLC | $43750809 | 804095 | 0,48% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $41924320 | 770526 | 0,46% | الأسهم |
| Capital Impact Advisors, LLC | $41061268 | 754664 | 0,45% | الأسهم |
| BlackRock, Inc. | $40753525 | 749008 | 0,45% | الأسهم |
| RHUMBLINE ADVISERS | $35723294 | 656559 | 0,39% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $35464438 | 651800 | 0,39% | الأسهم |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $34721830 | 639680 | 0,38% | الأسهم |
| MARSHALL WACE, LLP | $34322590 | 630814 | 0,38% | الأسهم |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $34315027 | 630675 | 0,38% | الأسهم |
| AMERIPRISE FINANCIAL INC | $32255716 | 592827 | 0,35% | الأسهم |
| BARCLAYS PLC | $31502574 | 578985 | 0,34% | الأسهم |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $31496480 | 578873 | 0,34% | الأسهم |
| Arbejdsmarkedets Tillaegspension | $30855911 | 567100 | 0,34% | الأسهم |
| Pictet Asset Management Holding SA | $30153926 | 555438 | 0,33% | الأسهم |
| California Public Employees Retirement System | $29366600 | 539728 | 0,32% | الأسهم |
| CAPITAL FUND MANAGEMENT S.A. | $28686856 | 527235 | 0,31% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $28655734 | 526663 | 0,31% | الأسهم |
| JANUS HENDERSON GROUP PLC | $26675806 | 621814 | 0,29% | الأسهم |
| Livforsakringsbolaget Skandia, Omsesidigt | $26502106 | 293703 | 0,29% | الأسهم |
| Woodline Partners LP | $26411049 | 485408 | 0,29% | الأسهم |
| Driehaus Capital Management LLC | $26025500 | 478322 | 0,28% | الأسهم |
| EULAV Asset Management | $25901500 | 476043 | 0,28% | الأسهم |
| Squarepoint Ops LLC | $25774398 | 473707 | 0,28% | الأسهم |
| Swiss National Bank | $25648874 | 471400 | 0,28% | الأسهم |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $25156355 | 462348 | 0,28% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24600555 | 452133 | 0,27% | الأسهم |
| IEQ CAPITAL, LLC | $24580697 | 451768 | 0,27% | الأسهم |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $23831580 | 438000 | 0,26% | الأسهم |
| Baird Financial Group, Inc. | $23565461 | 433109 | 0,26% | الأسهم |
| FRANKLIN RESOURCES INC | $23480472 | 431547 | 0,26% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23347331 | 429100 | 0,26% | عقد خيار الشراء |
| Assenagon Asset Management S.A. | $23324098 | 428673 | 0,26% | الأسهم |
| BANK OF NOVA SCOTIA | $22837676 | 419730 | 0,25% | الأسهم |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $22615516 | 415650 | 0,25% | الأسهم |
| South Street Advisors LLC | $22275019 | 409392 | 0,24% | الأسهم |
| Bridgewater Associates, LP | $21810738 | 400859 | 0,24% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $21480143 | 394783 | 0,23% | الأسهم |
| ROYAL BANK OF CANADA | $20031000 | 368153 | 0,22% | الأسهم |
| SEI INVESTMENTS CO | $19897640 | 365698 | 0,22% | الأسهم |
| LAZARD ASSET MANAGEMENT LLC | $18664208 | 343029 | 0,20% | الأسهم |
| Nuveen, LLC | $18299226 | 336321 | 0,20% | الأسهم |
| Nuveen Asset Management, LLC | $18252629 | 548127 | 0,20% | الأسهم |
| NFJ INVESTMENT GROUP, LLC | $17880160 | 328619 | 0,20% | الأسهم |
| SAWGRASS ASSET MANAGEMENT LLC | $17808447 | 327301 | 0,19% | الأسهم |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $17565616 | 322838 | 0,19% | الأسهم |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $17472485 | 407379 | 0,19% | الأسهم |
| ING GROEP NV | $16943274 | 311400 | 0,19% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16529758 | 303800 | 0,18% | عقد خيار البيع |
| Brandywine Global Investment Management, LLC | $16490117 | 376229 | 0,18% | الأسهم |
| CAPTRUST FINANCIAL ADVISORS | $16488532 | 303042 | 0,18% | الأسهم |
| INTECH INVESTMENT MANAGEMENT LLC | $16262224 | 298883 | 0,18% | الأسهم |
| HighTower Advisors, LLC | $15842121 | 291162 | 0,17% | الأسهم |
| SEIZERT CAPITAL PARTNERS, LLC | $15411796 | 283253 | 0,17% | الأسهم |
| Trexquant Investment LP | $14974122 | 275209 | 0,16% | الأسهم |
| Clark Capital Management Group, Inc. | $14792882 | 271878 | 0,16% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $14763381 | 344215 | 0,16% | الأسهم |
| VAN ECK ASSOCIATES CORP | $14270709 | 262281 | 0,16% | الأسهم |
| GLOBEFLEX CAPITAL L P | $13874169 | 254993 | 0,15% | الأسهم |
| Sofinnova Investments, Inc. | $13831022 | 254200 | 0,15% | عقد خيار البيع |
| JANE STREET GROUP, LLC | $13815570 | 253916 | 0,15% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $13724052 | 252234 | 0,15% | الأسهم |
| Voleon Capital Management LP | $13682047 | 251462 | 0,15% | الأسهم |
| BLAIR WILLIAM & CO/IL | $13233352 | 243215 | 0,14% | الأسهم |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $13027000 | 239418 | 0,14% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12745021 | 297156 | 0,14% | الأسهم |
| MERITAGE PORTFOLIO MANAGEMENT | $12679099 | 289279 | 0,14% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $12516694 | 230044 | 0,14% | الأسهم |
| Susquehanna Portfolio Strategies, LLC | $12500643 | 229749 | 0,14% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $12035492 | 221200 | 0,13% | عقد خيار الشراء |
| Illinois Municipal Retirement Fund | $11750764 | 215967 | 0,13% | الأسهم |
المطلعون على الشركة 43 من المطلعين · مسؤولون 22 · مديرون 10
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Michael Morrissey | President and CEO | 18 مايو، 2026 G | 2004327 | 0 | 0 | $0 |
| Christopher J. Senner | EVP and CFO | 18 مايو، 2026 S | 952317 | 0 | 3 | $-4556048 |
| Deborah Burke | SVP & Chief Financial Officer | 15 نوفمبر، 2014 M | 18156 | 0 | 0 | $0 |
| Frank Karbe | EVP and CFO | 15 فبراير، 2014 M | 93990 | 0 | 0 | $0 |
| Kristine M Ball | Controller & Interim CFO | 10 ديسمبر، 2003 A | 4913 | 0 | 0 | $0 |
| Patrick J. Haley | EVP, Commercial | 20 مايو، 2026 S | 357638 | 0 | 7 | $-7597268 |
| Brenda Hefti | SVP and General Counsel | 18 مايو، 2026 S | 106762 | 0 | 2 | $-1154264 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 16 مايو، 2025 M | 465393 | 0 | 0 | $0 |
| Jeffrey Hessekiel | EVP & General Counsel | 15 مايو، 2025 S | 693396 | 0 | 0 | $0 |
| Vicki L Goodman | EVP, Prod Dev & Med Aff &CMO | 3 إبريل، 2023 A | 307654 | 0 | 0 | $0 |
| Peter Lamb | EVP, Scientific Strategy & CSO | 15 ديسمبر، 2022 M | 410958 | 0 | 0 | $0 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | 26 يوليو، 2021 M | 689078 | 0 | 0 | $0 |
| Pamela A Simonton | EVP and General Counsel | 15 نوفمبر، 2013 M | 17139 | 0 | 0 | $0 |
| Lupe M Rivera | EVP, Operations | 15 أغسطس، 2011 M | 19219 | 0 | 0 | $0 |
| Frances K Heller | EVP, Business Development | 15 مايو، 2011 M | 17125 | 0 | 0 | $0 |
| Ian D Malcolm | VP, STRATEGIC MARKETING | 8 ديسمبر، 2006 A | — | 0 | 0 | $0 |
| Christoph Pereira | VP, Legal Affairs & Secretary | 8 ديسمبر، 2006 A | — | 0 | 0 | $0 |
| Jeffrey Latts | Executive VP, Development | 8 ديسمبر، 2006 A | — | 0 | 0 | $0 |
| Gregory Plowman | Sr VP, CSO | 13 ديسمبر، 2004 A | — | 0 | 0 | $0 |
| Steven P James | Sr VP, Commercial Ops | 10 ديسمبر، 2003 A | — | 0 | 0 | $0 |
| Jane M Green | VP, Corp Communications | 10 ديسمبر، 2003 A | — | 0 | 0 | $0 |
| Geoffrey M Duyk | Pres R&D & CSO | 4 نوفمبر، 2003 S | 941355 | 0 | 0 | $0 |
| Alan M Garber | مدير | 21 مارس، 2024 M | 35703 | 0 | 0 | $0 |
| Jacqueline Wright | مدير | 1 يونيو، 2023 A | 51756 | 0 | 0 | $0 |
| Carl B Feldbaum | مدير | 9 فبراير، 2023 M | 18701 | 0 | 0 | $0 |
| Lance Willsey | مدير | 26 مايو، 2022 A | 424415 | 0 | 0 | $0 |
| Vincent T Marchesi | مدير | 26 مايو، 2022 A | 93989 | 0 | 0 | $0 |
| Charles Cohen | مدير | 6 يوليو، 2021 M | 261375 | 0 | 0 | $0 |
| George A Scangos | مدير | 18 مايو، 2020 S | 714717 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | مدير | 7 سبتمبر، 2005 S | 584519 | 0 | 0 | $0 |
| Mary C Beckerle | — | 10 أغسطس، 2026 S | 16079 | 0 | 4 | $-1932572 |
| Sue Gail Eckhardt | — | 1 يونيو، 2026 S | 16079 | 0 | 2 | $-660828 |
| Jack L Wyszomierski | — | 1 يونيو، 2026 S | 284384 | 0 | 2 | $-4580661 |
| Tomas J. Heyman | — | 27 مايو، 2026 A | 50649 | 0 | 0 | $0 |
| Bob Oliver | — | 27 مايو، 2026 A | 29487 | 0 | 2 | $-1325340 |
| Julie Smith | — | 27 مايو، 2026 A | 28957 | 0 | 3 | $-4687346 |
| Maria C Freire | — | 27 مايو، 2026 A | 109186 | 0 | 1 | $-949164 |
| Stelios Papadopoulos | — | 27 مايو، 2026 A | 1197595 | 0 | 1 | $-4355000 |
| George Poste | — | 27 مايو، 2026 A | 127199 | 0 | 1 | $-2742600 |
| Dana Aftab | — | 26 مايو، 2026 S | 594741 | 0 | 4 | $-7701255 |
| Frank Mccormick | — | 6 ديسمبر، 2013 A | — | 0 | 0 | $0 |
| Scott J. Garland | — | 18 سبتمبر، 2013 A | — | 0 | 0 | $0 |
| Jason S Fisherman | — | 8 سبتمبر، 2005 S | 7881 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 4 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. | 14 أغسطس، 2026 | 5,60% | تعديل | — | SEC |
| Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 إيداعات | 5 يناير، 2026 | 5,90% | تعديل | — | SEC |
| Caligan Partners LP, David Johnson ×3 إيداعات | 2 يونيو، 2023 | — | إيداع أولي | — | SEC |
| شخص مُبلِّغ لم يُكشف عنه | 29 نوفمبر، 2001 | — | إيداع أولي | اندماج واستحواذ / بيع | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 152 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| SAWG · ETF Series Solutions | 2,82% | 1599 NS | 30 إبريل، 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,78% | 96885 NS | 31 مايو، 2026 | N-PORT |
| MCOW · Pacer Funds Trust | 2,38% | 528 NS | 30 إبريل، 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,24% | 441186 NS | 30 إبريل، 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,01% | 2722 NS | 30 إبريل، 2026 | N-PORT |
| AZTD · Tidal Trust I | 1,92% | 18950 NS | 30 إبريل، 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,74% | 23148 NS | 30 إبريل، 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,61% | 1596 NS | 30 إبريل، 2026 | N-PORT |
| BUL · Pacer Funds Trust | 1,45% | 41520 NS | 30 إبريل، 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,39% | 306870 NS | 30 إبريل، 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,36% | 5563 NS | 30 إبريل، 2026 | N-PORT |
| COWG · Pacer Funds Trust | 1,26% | 616432 NS | 30 إبريل، 2026 | N-PORT |
| TAX · EA Series Trust | 1,13% | 5692 NS | 29 مايو، 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,07% | 829382 NS | 30 إبريل، 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 1,03% | 32938 NS | 31 مايو، 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 1,00% | 116281 NS | 30 إبريل، 2026 | N-PORT |
| AGNG · Global X Funds | 0,92% | 14988 NS | 31 مايو، 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 15171 NS | 31 مايو، 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,90% | 25550 NS | 30 إبريل، 2026 | N-PORT |
| FLOW · Global X Funds | 0,90% | 5093 NS | 31 مايو، 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,88% | 16470 NS | 30 إبريل، 2026 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 45672 NS | 30 إبريل، 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,69% | 7149 NS | 31 مايو، 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,68% | 82717 NS | 31 مايو، 2026 | N-PORT |
| BIB · ProShares Trust | 0,66% | 9600 NS | 31 مايو، 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,64% | 4091 NS | 31 مايو، 2026 | N-PORT |
| VUSE · ETF Series Solutions | 0,63% | 85930 NS | 31 مايو، 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,60% | 2080 NS | 30 إبريل، 2026 | N-PORT |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,58% | 255026 NS | 31 مايو، 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,53% | 19762 NS | 31 مايو، 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0,51% | 502 NS | 30 إبريل، 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,48% | 64828 NS | 30 إبريل، 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,47% | 5095 NS | 30 إبريل، 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,44% | 30864 NS | 30 إبريل، 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,41% | 47960 NS | 30 إبريل، 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,39% | 47706 NS | 31 مايو، 2026 | N-PORT |
| GQQQ · EA Series Trust | 0,38% | 11012 NS | 29 مايو، 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 37231 NS | 30 إبريل، 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 36776 NS | 30 إبريل، 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,34% | 29826 NS | 30 إبريل، 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,34% | 44252 NS | 30 إبريل، 2026 | N-PORT |
| MVV · ProShares Trust | 0,28% | 8976 NS | 31 مايو، 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,28% | 11940 NS | 31 مايو، 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,27% | 37832 NS | 30 إبريل، 2026 | N-PORT |
| SXQG · EXCHANGE TRADED CONCEPTS TRUST | 0,26% | 3540 NS | 31 مايو، 2026 | N-PORT |
| AVLV · AMERICAN CENTURY ETF TRUST | 0,26% | 666398 NS | 31 مايو، 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0,25% | 13506 NS | 29 مايو، 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,24% | 703070 NS | 31 مايو، 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,24% | 127845 NS | 30 إبريل، 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,23% | 4301 NS | 30 إبريل، 2026 | N-PORT |